Since 1 November 2019, Federico Chinni is the new CEO of UCB Italia, a biopharmaceutical company that develops innovative solutions for the treatment of serious diseases in the areas of immunology and neurology.
PharmaStar – November 20, 2019
“It is a great honor for me to take over the leadership of our branch” – he declares Federico Chinni. "As 
UCB Italia, we will have to contribute to the fascinating challenge of 6 global launches in 6 years, a challenge that we can only overcome by working together, with a model based on agility in the decision-making process and on the transversal nature of skills and roles."
Born in 1971, married, 2 daughters, Federico Chinni graduated in Law from the University of Bologna. He has developed a twenty-year professional career in multinational companies, first in leading companies in the biomedical sector and then, since 2012, in the pharmaceutical sector, where he held managerial roles of increasing responsibility, both nationally and internationally. At UCB since 2018, he served as director of the neurology division until his promotion.
The appointment of Federico Chinni comes at a particularly positive moment for UCB: “A few days ago the news of the positive opinion of the CHMP on romosozumab and that of the phase III results of bimekizumab, which open up very promising scenarios for affected patients, from fragility fractures and psoriasis, respectively,” comments Chinni.
